GlaxoSmithKline is providing refunds for charges above 340B ceiling prices on nine NDCs for purchases during Q1 2020.

GSK Providing Refunds for 340B Overcharges During Q1 2020

Drug manufacturer GlaxoSmithKline is providing refunds for charges above 340B ceiling prices on nine NDCs for purchases during Q1 2020.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×

*Sign up for news summaries and alerts from 340B Report